Artiva Biotherapeutics has discontinued development of its experimental cell therapy AlloNK and eliminated 94% of its workforce following two patient deaths and longer-term efficacy results that couldn’t meet the company’s expectations.
The San Diego-based biotechnology company had been investigating AlloNK, an allogeneic natural killer (NK) cell therapy that does not involve genetic modification, for rheumatoid arthritis (RA) and other autoimmune conditions driven by B cells. Artiva had planned to launch a vital Phase 3 trial in RA this year, but a reassessment of the treatment’s overall risks and potential benefits led the company to abandon those plans.
The decision followed a deterioration in the outlook for both safety and efficacy. Extended follow-up showed that AlloNK did not produce the sustained clinical responses Artiva considered necessary to justify further development.
Two patient deaths also contributed to concerns about the program. In one case, a participant in the Phase 2a basket study experienced a fatal neurological event. Both the treating investigator and an independent safety evaluation concluded that the death was likely associated with fludarabine, a chemotherapy agent used in the treatment regimen to prepare patients for cell therapy by reducing existing immune cells. Following the incident, the U.S. Food and Drug Administration asked Artiva to suspend enrollment and dosing in the Phase 2a study.
A second participant died suddenly approximately two months after beginning treatment. The investigator determined that this death was unrelated to AlloNK or any other component of the study regimen. The cause remains undetermined.
Although Artiva has other programs in its pipeline, AlloNK had been central to the company’s strategy. Its discontinuation has prompted substantial organizational changes, including the elimination of nearly its entire workforce. Artiva reported 115 full-time employees as of June 30.
The company has also begun reviewing strategic alternatives. Its board is considering options involving the existing business as well as potential transactions, including a merger, the sale of assets or liquidation.
The abrupt change in direction follows a period of significant investment and ambitious development plans. Artiva raised $300 million in May and, as recently as September, outlined plans to release additional clinical findings across several indications and begin Phase 3 testing in RA before the end of 2026.
At the end of September, the company held just over $319 million in cash. Its financial resources and Nasdaq listing could be relevant to parties evaluating a potential transaction as Artiva considers its next steps.
The AlloNK setback comes amid wider challenges for companies pursuing cell therapies for autoimmune diseases. Two months earlier, Bristol Myers Squibb and Novartis separately paused development of CAR-T treatments in this area. Novartis halted its CD19-targeted program after three deaths associated with serious immune effector cell-associated hemophagocytic syndrome.
Artiva, Bristol Myers Squibb and Novartis had invested in autoimmune cell therapies after research suggested that approaches capable of depleting B cells could produce durable clinical responses. Artiva’s decision highlights the difficulty of translating that promise into treatments with a sufficiently favorable safety profile and sustained benefits to support continued clinical development.
Artiva Discontinues Cell Therapy Following Patient Deaths
Artiva Biotherapeutics has faced a major setback after discontinuing its cell therapy program following two patient deaths associated with clinical trial treatment. The decision marks a significant change in Artiva’s development strategy and highlights the risks involved in advancing experimental cell-based therapies. The company is also conducting a substantial workforce reduction as it reassesses its research priorities, financial resources, and future operations. The developments have drawn attention to clinical trial safety, the challenges of developing innovative cancer treatments, and the difficult decisions biotechnology companies must make when serious adverse events occur.
